Valvular & structural heart diseaseRandomised controlled trial
Three-Year Follow-Up of the NOTION-2 Trial: Transcatheter Aortic Valve Replacement (TAVR) Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis
- Randomised controlled trial (3-year follow-up of the NOTION-2 trial)
- 1:1 randomisation
Authors' conclusion
For patients age 60 to 75 years with severe aortic stenosis who are at low surgical risk, 3-year clinical outcomes are similar between TAVR and surgery.
Study context
- Population
- Low-risk patients aged 60–75 years with severe tricuspid or bicuspid AS (mean age 71.1 years; mean STS PROM 1.2%)
- Participants
- 370 patients
- Comparison
- TAVR vs SAVR
- Primary endpoint
- Composite of death, stroke, or procedure-, valve-, or HF-related hospitalization
- Follow-up
- Up to 3 years
Primary result
As reported in the abstract
Hazard ratio
1.3
95% CI 0.8–2.2%
By group
TAVR vs Surgery
HR 1.3 (95% CI 0.8–2.2%)
Further findings
Primary composite, tricuspid AS (subgroup) · up to 3 years
Bioprosthetic valve failure
| Outcome | TAVR | Surgery | HR (95% CI) | |
|---|---|---|---|---|
| Primary composite, bicuspid AS (subgroup) · up to 3 years · statistically nonsignificant | 20.4% | 7.8% | 2.9 (0.9–9.0) | |
| Moderate or greater structural valve deterioration · up to 3 years | 4.5% | 5.2% | 1.2 (0.4–3.1) | |
| 0.10.31310Hazard ratio (log scale) |
Original publication
Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis. Circulation. Published 30 August 2025. doi:10.1161/circulationaha.125.076678
Summarised from the published abstract; every number is checked against it